Q-omics provides the consensus-scored MIR3135B profile across patient tissues and cancer cell-line models. MIR3135B expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR3135B is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR3135B RNA expression shows 6,545 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where MIR3135B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3135B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3135B survival associations across molecular data types. MIR3135B RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3135B RNA expression–survival associations across cancer types. High MIR3135B expression shows unfavorable associations in UVM, KIRP, STAD and UCS, but favorable associations in LUAD and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR3135B RNA expression.
This table summarizes MIR3135B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3135B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3135B shows lower tumor expression in LUSC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher MIR3135B RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p < 0.001).
This table shows molecular features associated with MIR3135B in patient tissues and cancer cell lines. In patient samples, MIR3135B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
